Halozyme Therapeutics (HALO) Gross Margin (2010 - 2026)
Halozyme Therapeutics (HALO) reported Gross Margin of 78.97% for Q1 2026, down 276.0% year-over-year from 44.87% in Q1 2025, and down 4.36% quarter-over-quarter from 82.56% in Q4 2025.
Halozyme Therapeutics (HALO) Gross Margin (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of Gross Margin data on file, last reported at 78.97% in Q1 2026.
- Gross Margin for Q1 2026 came in at 78.97%, down 276.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 82.79% (down 66.0% YoY), and the FY2025 annual result was 83.62%, down 68.0% from the prior year.
- Gross Margin slipped to 78.97% in Q1 2026 per HALO's latest filing, from 82.56% in the prior quarter.
- Over five years, Gross Margin peaked at 86.42% in Q1 2022 and troughed at 74.62% in Q3 2023.
- A 5-year average of 80.97% and a median of 81.73% in 2025 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2024: Gross Margin sank 811 bps in 2023, then soared 862 bps in 2024.
- A 5-year view of Gross Margin shows it stood at 76.79% in 2022, then increased by 1 bps to 77.27% in 2023, then gained by 11 bps to 85.89% in 2024, then decreased by 4 bps to 82.56% in 2025, then retreated by 4 bps to 78.97% in 2026.
- Business Quant data shows HALO's Gross Margin at 78.97% in Q1 2026, 82.56% in Q4 2025, and 84.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 78.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.97% |
| Dec 31, 2025 | 82.56% |
| Sep 30, 2025 | 84.41% |
| Jun 30, 2025 | 85.77% |
| Mar 31, 2025 | 81.73% |
| Dec 31, 2024 | 85.89% |
| Sep 30, 2024 | 82.96% |
| Jun 30, 2024 | 82.88% |
| Mar 31, 2024 | 85.54% |
| Dec 31, 2023 | 77.27% |
| Sep 30, 2023 | 74.62% |
| Jun 30, 2023 | 77.35% |
| Mar 31, 2023 | 78.31% |
| Dec 31, 2022 | 76.79% |
| Sep 30, 2022 | 77.36% |
| Jun 30, 2022 | 77.72% |
| Mar 31, 2022 | 86.42% |
| Dec 31, 2021 | 78.84% |
| Sep 30, 2021 | 83.95% |
| Jun 30, 2021 | 83.13% |